The Danish pharma giant posted impressive data for amycretin one month after the disappointing readout of CagriSema.

Most people know that GLP-1 receptor agonist medications like Ozempic and Wegovy can cause relatively minor side effects like ...

Allurion Technologies (NYSE: ALUR) shares are moving higher Friday potentially after after the company announced plans to conduct a clinical study evaluating the combination of its Allurion Program ...

Novo Nordisk stock is paring its year-over-year deficit on positive early stage trial results for the company's new weight ...

A novel GLP-1 and amylin receptor agonist featured a safety profile similar to other incretin-based therapies and conferred a ...

In the trial, patients who received a once-weekly 20 mg injection of amycretin over 36 weeks saw an impressive 22% reduction ...

Amycretin could give Novo a buzzy product in an newly competitive obesity market. It works similarly to existing GLP-1 ...

The readout comes on the heels of CagriSema’s disappointing Phase III performance, where it missed Novo’s projection of 25% ...

For people with diabetes, the use of GLP-1 RAs is associated with reduced risk for certain disorders and conditions.

Ozempic and Wegovy do the same thing as GLP-1 would normally do for you — but to enable them to treat diabetes and obesity, ...

Novo Nordisk (NVO) announced topline results from a phase 1b/2a clinical trial with amycretin, a unimolecular GLP-1 and amylin receptor agonist ...

The author of a new guidebook on GLP-1s and other experts share their tips for how clinicians can optimize patient success ...